Biocon Limited (BIOCON.BO)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Kiran Mazumdar-Shaw B.Sc (Hons), B.Sc. | Founder & Executive Chairperson | 38.43M | -- | 1953 |
| Mr. Siddharth Mittal BCom, CA, CPA | MD, CEO & Director | 57.31M | -- | 1978 |
| Mr. Mukesh Kamath | Chief Financial Officer | -- | -- | -- |
| Mr. Arun Gupta | Head of Operations | -- | -- | -- |
| Mr. Atanu Roy | Group Chief Information Officer | -- | -- | -- |
| Mr. Saurabh Paliwal | Head of Investor Relations | -- | -- | -- |
| Ms. Seema Shah Ahuja BA, MBA | Global Head of Communications & Corporate Brand | -- | -- | 1966 |
| Ms. Maninder Kapoor Puri | Head of Human Resources | -- | -- | 1973 |
| Mr. Paul Vazhayil Thomas | Chief Commercial Officer, U.S. & Portfolio Strategy & Business Dev, Adv mkts of Biosimilars Business | -- | -- | 1973 |
| Mr. Abhijit Zutshi | Commercial Head of Biocon Global Generics | -- | -- | -- |
Biocon Limited
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 16,315
Description
Biocon Limited, together with its subsidiaries, engages in the manufacture and sale of biotechnology products and research services in India, Brazil, Singapore, and internationally. It operates through four segments: Generics, Novel Biologics, Biosimilars, and Research Services. The company offers generic formulations and API products, including anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology, and other products; novel biologics products, such as head and neck cancer molecule; novel pipeline products comprising psoriasis molecules; and biosimilars products consisting of insulins, trastuzumab, pegfilgrastim, and bevacizumab. It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal healthcare, consumer good, and agrochemical companies. Biocon Limited was incorporated in 1978 and is headquartered in Bengaluru, India.
Corporate Governance
Upcoming Events
May 8, 2025 at 10:59 AM UTC
Biocon Limited Earnings Date
Recent Events
July 5, 2024 at 12:00 AM UTC
Ex-Dividend Date